Blair William & Co. IL cut its position in Medtronic plc (NYSE:MDT) by 1.6% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 494,891 shares of the medical technology company’s stock after selling 8,036 shares during the quarter. Blair William & Co. IL’s holdings in Medtronic were worth $57,971,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Diversified LLC purchased a new stake in shares of Medtronic during the 4th quarter valued at $25,000. Spectrum Management Group LLC raised its position in shares of Medtronic by 317.5% during the 3rd quarter. Spectrum Management Group LLC now owns 263 shares of the medical technology company’s stock valued at $27,000 after buying an additional 200 shares in the last quarter. Clark Financial Advisors purchased a new stake in shares of Medtronic during the 4th quarter valued at $29,000. Financial Avengers Inc. purchased a new stake in shares of Medtronic during the 4th quarter valued at $29,000. Finally, Catalyst Private Wealth LLC purchased a new stake in shares of Medtronic during the 3rd quarter valued at $31,000. Institutional investors and hedge funds own 79.17% of the company’s stock.
NYSE:MDT opened at $115.74 on Tuesday. The company has a 50-day moving average price of $116.82 and a 200-day moving average price of $110.18. Medtronic plc has a 12 month low of $72.13 and a 12 month high of $120.53. The company has a current ratio of 2.16, a quick ratio of 1.79 and a debt-to-equity ratio of 0.52. The stock has a market cap of $155.79 billion, a price-to-earnings ratio of 44.18, a P/E/G ratio of 3.65 and a beta of 0.70.
Several research firms recently commented on MDT. Piper Sandler increased their target price on shares of Medtronic from $120.00 to $130.00 and gave the company an “overweight” rating in a report on Tuesday, November 24th. The Goldman Sachs Group raised shares of Medtronic from a “sell” rating to a “neutral” rating and increased their target price for the company from $100.00 to $119.00 in a report on Tuesday, December 15th. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell increased their target price on shares of Medtronic from $120.00 to $128.00 in a report on Wednesday, November 25th. Morgan Stanley raised shares of Medtronic from an “equal weight” rating to an “overweight” rating and set a $140.00 target price on the stock in a report on Tuesday, December 15th. Finally, Raymond James increased their target price on shares of Medtronic from $115.00 to $122.00 and gave the company an “outperform” rating in a report on Wednesday, November 25th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, twenty have given a buy rating and one has issued a strong buy rating to the company. Medtronic has a consensus rating of “Buy” and an average target price of $120.93.
In other news, SVP Carol A. Surface sold 15,000 shares of Medtronic stock in a transaction that occurred on Monday, December 28th. The shares were sold at an average price of $114.90, for a total value of $1,723,500.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Robert John White sold 10,930 shares of the business’s stock in a transaction that occurred on Friday, December 18th. The shares were sold at an average price of $115.46, for a total transaction of $1,261,977.80. Following the sale, the executive vice president now owns 55,852 shares of the company’s stock, valued at $6,448,671.92. The disclosure for this sale can be found here. Company insiders own 0.52% of the company’s stock.
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiac and Vascular Group, Minimally Invasive Therapies Group, Restorative Therapies Group, and Diabetes Group.
Read More: Cost of Capital Explained
Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic plc (NYSE:MDT).
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.